Search results
Results from the WOW.Com Content Network
The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022. [5] Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7]
Shares in Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019 and spun off from the British drugmaker in 2022, fell 1.2% to 388 pence in morning ...
(Reuters) -Haleon plans to buy back 500 million pounds ($633 million) of its shares this year amid firm demand for its products and progress in reducing debt, sending the British consumer ...
GSK earlier this year sold 240 million shares in Haleon to raise about 804 million pounds ($1 billion), and lowered its stake from 12.9% it initially retained in the business.
British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The sale was at a discount of about 2.5% to Haleon's last close of 332.4 pence on Thursday. GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. The company ...
Haleon was formed in 2019 by merging GSK and Pfizer's consumer healthcare businesses. The disposal will be conducted via placing of shares in Haleon to institutional investors.